Showing 1481-1490 of 2046 results for "".
- Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMDhttps://modernod.com/news/opthea-treats-final-patient-in-phase-3-coast-trial-for-wet-amd/2482668/Opthea announced that it has completed the final week 52 patient visit in COAST, the first of two phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatm
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Oculis Begins Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/Oculis Holding announced 'First Patient First Visit' (FPFV) in the OCS-01 phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the phase 3 OPTIMIZE-2 trial is intended to support the company’s NDA submission to the FDA. If ap
- Oculis Commences Stage 2 of Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in DMEhttps://modernod.com/news/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-dme/2482015/Oculis Holding announced that the 'First Patient First Visit (FPFV)' in stage 2 of its phase 3 DIAMOND-1 trial evaluating OCS-01 for the treatment of DME. DIAMOND-1 is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and sa
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- AI Can Identify Heart Disease From an Eye Scanhttps://modernod.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack, according to a University of Leeds, UK, news release. Doctors have recognized th
- Kubota Vision Initiates PBOS Prospective Study in Patientshttps://modernod.com/news/kubota-vision-initiates-pbos-prospective-study-in-patients/2480577/Kubota Vision announced that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using the company's Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device. The study is being led by S
- Updated Cataract PPP Raises Questions About Same-Day Bilateral Cataract Surgery and Office-based Cataract Surgeryhttps://modernod.com/news/updated-cataract-ppp-raises-questions-about-same-day-bilateral-cataract-surgery-and-office-based-cataract-surgery/2480467/The American Academy of Ophthalmology recognizes that immediate sequential bilateral cataract surgery (ISBCS) has the potential for some positive implications for patients. These include reduced out-of-pocket expense and fewer total visits to health care facilities. ISBCS has been adopted to a gr
- AMA: Look to Ophthalmology for a Glimpse of Telemedicine’s Futurehttps://modernod.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/Early on in the COVID-19 pandemic, ophthalmology struggled to adapt to telemedicine. It just wasn’t set up for virtual visits. “Ophthalmology is an exam-heavy specialty, and we really rely on all the clinical clues that we capture—either at the slit lamp, or looking at the retina, or check
- OneSight Partners With Anthem Blue Cross and Blue Shield Foundation to Provide Free Eye Exams and Glasses in Cincinnatihttps://modernod.com/news/onesight-partners-with-anthem-blue-cross-and-blue-shield-foundation-to-provide-free-eye-exams-and-glasses-in-cincinnati/2479049/Preventative care visits have dropped significantly over the course of the pandemic, and this is especially true in under-served communities. That’s why the Anthem Blue Cross and Blue Shield Foundation teamed up with OneSight, a leading global vision care nonprofit, to provide free eye exams and